The regulatory landscape for Batten disease treatment market is complex and dynamic, with regulatory bodies such as the FDA and EMA playing a key role in the approval process for new therapies. Due to the rarity of the disease, regulatory bodies often provide incentives to pharmaceutical companies for the development of therapies, such as orphan drug designation and accelerated approval...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian